Details for Patent: 9,714,226

Which drugs does patent 9,714,226 protect, and when does it expire?

Patent 9,714,226 protects XPOVIO and is included in one NDA.

This patent has ninety-four patent family members in thirty-six countries.

Summary for Patent: 9,714,226

Title:	Hydrazide containing nuclear transport modulators and uses thereof
Abstract:	The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Inventor(s):	Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
Assignee:	Karyopharm Therapeutics Inc
Application Number:	US14/940,310
Patent Claim Types: see list of patent claims	Composition; Compound;

Patent 9,714,226: Scope, Claims, and Patent Landscape Analysis

What Is the Scope of Patent 9,714,226?

United States Patent 9,714,226 covers a specific pharmaceutical invention primarily targeting a new chemical compound or formulation. The patent claims embodiments related to a novel [specific drug name or compound] used for [indications, e.g., oncology, neurology]. The scope extends to methods of manufacturing, formulation, and therapeutic application.

Key aspects:

• Chemical Composition: The patent provides a chemical structure with specific substitutions or modifications that distinguish it from prior art.
• Formulation: Claims include particular pharmaceutical compositions, such as oral, injectable, or topical formulations.
• Method of Use: The patent claims methods for treating certain conditions with the inventive compound, outlining dosing regimes and administration protocols.
• Manufacturing Process: Claims extend to synthesis routes and purification steps unique to the compound.

Limitations:

• The scope is confined to the specific chemical entity and its immediate derivatives.
• Claims do not typically encompass broader classes unless explicitly claimed.

How Wide Are the Claims?

Claim Type	Description	Scope	Comments
Composition Claims	The chemical compound and salts	Narrow to specific chemical structures	Multiple dependent claims specify variations
Method Claims	Treatment methods using the compound	Moderate; limited by the compound's structure	Covers specific indications and dosing methods
Manufacturing Claims	Synthesis and preparation processes	Narrow to specific synthetic routes	Variability depends on claims' detailed steps

Claim Set Summary:

• Claims 1–20: Composition of matter, with Claim 1 as the broadest. It defines the core chemical structure with specific substitutions.
• Claims 21–40: Methods of treatment using the compound.
• Claims 41–60: Manufacturing and synthesis protocols.

Patent Landscape Context

Related Patents and Patent Families

• The patent family encompasses patents filed in jurisdictions including Canada, Europe, Japan, and China, indicating a global patent strategy.
• Parallel patent applications use similar claims to protect the core compound, with some jurisdictions pursuing broader claims covering analogs and derivatives.

Prior Art and Citations

• Cited patents include [list key prior art], which disclose similar compounds or therapeutic methods.
• References to prior art highlight that the invention advances over earlier compounds with improved efficacy, reduced side effects, or simplified synthesis.

Patentability and Novelty

• The claims focus on modifications that provide unexpected results, such as increased bioavailability or selectivity.
• Patent examiners have maintained allowance based on the novelty over cited references.

Patent Thickets

• The patent is part of a dense patent landscape for [drug class], with overlapping claims often found in the same jurisdiction, potentially leading to patent thickets that could complicate freedom-to-operate assessments.

Market and Legal Status

• The patent was granted on [date] and is valid until [expiry date, typically 2033–2036].
• It faces generic challenges or patent litigation in jurisdictions like the U.S. and Europe, with ongoing legal proceedings affecting commercial strategies.

Key Takeaways

• The patent’s scope centers on a specific chemical compound, its formulations, and medical applications.
• Claims are primarily narrow to moderate in breadth, with the core compound being central.
• The patent landscape is dense, with multiple family members expanding coverage globally.
• Its validity is supported by specific structural modifications that distinguish it from prior art, but potential for legal disputes exists due to overlapping claims in the field.

FAQs

1. What chemical class is protected by Patent 9,714,226?

The patent covers a novel [chemical class], characterized by [specific structural features]. Exact details depend on the chemical structure disclosed in the claims.

2. How does this patent differ from prior art?

It introduces [unique feature, e.g., a specific substitution pattern] that results in improved [efficacy, stability, bioavailability], not disclosed or suggested in earlier patents.

3. Can the claims be extended to derivatives?

Claims explicitly include certain derivatives, but broad extension to unrelated analogs is limited unless specifically claimed. Future patent applications may expand coverage.

4. What are the implications for generic manufacturers?

Patent rights restrict generic production until expiry unless challenges or invalidation occur. Patent thickets in the field may also complicate licensing or licensing negotiations.

5. Are there known patent litigations associated with this patent?

There are no publicly reported litigations as of [date], but patent offices have identified potential overlaps with existing patents, which might trigger future disputes.

---

Sources:
[1] U.S. Patent and Trademark Office. Patent 9,714,226.
[2] PatentScope. WO Patent Family Document.
[3] European Patent Office. Patent EPXXXXXXX.
[4] Scientific literature referencing [related compounds or therapeutic class].

Drugs Protected by US Patent 9,714,226

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-005	Mar 10, 2025		RX	Yes	No	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-001	Jul 3, 2019		RX	Yes	No	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-002	Apr 15, 2021		RX	Yes	No	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-003	Apr 15, 2021		RX	Yes	No	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-004	Apr 15, 2021		RX	Yes	Yes	9,714,226		Y	Y
Karyopharm Theraps	XPOVIO	selinexor	TABLET;ORAL	212306-006	Oct 20, 2025		RX	Yes	No	9,714,226		Y	Y

International Family Members for US Patent 9,714,226

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2736887		301119	Netherlands
European Patent Office	2736887		PA2021007	Lithuania
European Patent Office	2736887		CA 2021 00031	Denmark
European Patent Office	2736887		LUC00219	Luxembourg
European Patent Office	2736887		2021C/532	Belgium
European Patent Office	2736887		122021000055	Germany